SCHEMBL2582045

SCHEMBL2582045

CCOC(=O)c1c(C)cccc1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.54
RXRB P28702 1/20 0.54
RXRG P48443 1/20 0.54
MAPT P10636 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
RAB9A P51151 2/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
NPC1 O15118 1/20 0.50
KMT2A Q03164 1/20 0.50
PPIA P62937 3/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
FOLH1 Q04609 1/20 0.49
LIPE Q05469 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11730888 0.89 NPC1 (0.50) RXRARXRBRXRGMAPTL3MBTL1
SCHEMBL8323146 0.87 CA12 (0.64) MAPTL3MBTL1MAPK1TDP1RAB9A
SCHEMBL27477949 0.85 RXRA (0.63) RXRARXRBRXRGMAPTL3MBTL1
SCHEMBL1097553 0.83 PPIA (0.56) RXRARXRBRXRGMAPTL3MBTL1
SCHEMBL11330009 0.82 L3MBTL1 (0.47) RXRARXRBRXRGMAPTL3MBTL1
SCHEMBL22438746 0.82 KMT2A (0.50) L3MBTL1TDP1RAB9ANPC1KMT2A
SCHEMBL3926837 0.82 TDP1 (0.58) MAPTL3MBTL1MAPK1TDP1KMT2A
SCHEMBL340937 0.81 HTT (0.69) MAPTL3MBTL1MAPK1TDP1NPC1
SCHEMBL6068448 0.80 TDP1 (0.59) MAPTL3MBTL1MAPK1TDP1RAB9A
SCHEMBL31643905 0.80 KDM4E (0.48) MAPTL3MBTL1TDP1RAB9AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 RXRA 1228/4885RXRB 1465/4885RXRG 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.